Artivion (AORT) Projected to Post Quarterly Earnings on Thursday

Artivion (NYSE:AORT) is projected to issue its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to post earnings of ($0.0612) per share and revenue of $120.97 million for the quarter. Interested persons can check the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Artivion (NYSE:AORT) last posted its quarterly earnings data on Thursday, August 6th. The company reported $0.13 EPS for the quarter. The business had revenue of $125.76 million for the quarter, compared to analysts’ expectations of $119.99 million. Artivion had a negative net margin of 0.67% and a positive return on equity of 6.07%. On average, analysts expect Artivion to post $0.45 EPS for the current fiscal year and $0.77 EPS for the next fiscal year.

Artivion Price Performance

AORT stock opened at $23.77 on Wednesday. The stock has a 50-day moving average price of $23.72 and a two-hundred day moving average price of $29.27. The stock has a market cap of $1.16 billion, a PE ratio of -339.52 and a beta of 1.31. The company has a current ratio of 3.47, a quick ratio of 2.51 and a debt-to-equity ratio of 0.82. Artivion has a 1 year low of $19.16 and a 1 year high of $48.25.

Wall Street Analysts Forecast Growth

Several research firms have recently weighed in on AORT. Canaccord Genuity Group upped their price objective on Artivion from $39.00 to $40.00 and gave the stock a “buy” rating in a research report on Tuesday, August 18th. Wall Street Zen lowered Artivion from a “hold” rating to a “sell” rating in a research report on Saturday, August 15th. Needham & Company LLC restated a “buy” rating and issued a $44.00 target price on shares of Artivion in a research note on Monday, July 20th. Weiss Ratings cut Artivion from a “sell (d+)” rating to a “sell (d-)” rating in a research note on Tuesday, August 11th. Finally, Jefferies Financial Group initiated coverage on Artivion in a research report on Tuesday, October 20th. They set a “buy” rating and a $31.00 price target for the company. Seven research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $42.86.

Insider Buying and Selling at Artivion

In other news, SVP Andrew M. Green sold 11,480 shares of the stock in a transaction dated Thursday, September 10th. The shares were sold at an average price of $24.97, for a total transaction of $286,655.60. Following the completion of the transaction, the senior vice president directly owned 40,160 shares in the company, valued at $1,002,795.20. This represents a 22.23% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Also, CEO James P. Mackin sold 70,000 shares of the firm’s stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $28.95, for a total value of $2,026,500.00. Following the completion of the transaction, the chief executive officer owned 877,275 shares of the company’s stock, valued at $25,397,111.25. The trade was a 7.39% decrease in their position. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 90,460 shares of company stock worth $2,557,366. Insiders own 6.30% of the company’s stock.

Artivion Company Profile

Artivion, Inc (NYSE: AORT) is a medical device and biotechnology company focused on developing and commercializing products used in cardiac and vascular surgery. Its portfolio includes implantable devices, surgical sealants, and human tissue products designed to treat diseases of the heart, aorta, and peripheral blood vessels.

The company’s products include On-X mechanical heart valves, aortic and vascular grafts, BioGlue surgical adhesive, and stent graft systems for aortic repair. Artivion also provides tissue preservation services and distributes cardiac and vascular allografts for use in reconstructive procedures.

Artivion was formerly known as CryoLife, a company founded in 1984, and adopted the Artivion name in 2021 to reflect its broader focus on aortic and cardiac care.